Trials / Completed
CompletedNCT00237250
Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 171 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- —
Summary
The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to placebo in lowering post-meal blood glucose levels in people with pre-diabetes who have high blood sugar levels after meals.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | vildagliptin |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2006-07-01
- Completion
- 2006-07-01
- First posted
- 2005-10-12
- Last updated
- 2012-05-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00237250. Inclusion in this directory is not an endorsement.